ArticleCancer cell2022
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 4 pooled it
30.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 4 syntheses or guidelines pooled it, 360 citations in OpenAlex.
- Fecal microbiota transplantation from psychiatric patients to mice - systematic review of methodologies and a call for standardization.Translational psychiatry · 2026Pooled it
- Intestinal fungal signatures and their impact on immune checkpoint inhibitor efficacy: a multi-cohort meta-analysis.NPJ biofilms and microbiomes · 2025Pooled it
- Predicting cancer-related mycobiome aspects in gastrointestinal cancers: a systematic review.Frontiers in medicine · 2024Pooled it
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Trial
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Isolation of Bacteria and Fungi from Human Pancreatic Tumors and Duodenum.Gut microbes · 2026Article
- The gut-pancreas axis: microbial dysbiosis as a pathogenic driver of diabetes and pancreatic cancer.Medical oncology (Northwood, London, England) · 2026Review
- Review
- Oral Fungal Infection Impacts Epithelial Innate Immunity to Promote Local and Distal Squamous Cell Carcinoma Progression.Cancer research · 2026Article
- Article
- Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.Nature cancer · 2026Article
- Microbiome: a driver of pancreatic inflammation and tumorigenesis.Trends in cancer · 2026Review
- Intratumoral Mycobacterium abscessus promotes cytidine deaminase mutagenesis in non-small cell lung cancer.Signal transduction and targeted therapy · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- ILC2s regulate a fibroblast progenitor niche in the pancreas.Science (New York, N.Y.) · 2026Article
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages.Cancer immunology research · 2026Article
- Malassezia restricta-Derived Extracellular Vesicles Drive Ovarian Cancer Progression Through JAK2/STAT3-Mediated M2 Macrophage Polarisation.Microbial biotechnology · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 3 institutions in 2 countries.
Aftab AlamDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Eric LevanduskiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Parker DenzDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Helena Solleiro VillavicencioDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Maulasri BhattaDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Lamees AlhorebiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Yali ZhangDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Eduardo Cortes GomezDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Brian MorrealeDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Sharon SenchanthisaiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Jun LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Steven G TurowskiDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Sandra SextonDepartment of Animal Resources, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Sheila Jani SaitDepartment of Cytogenetics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Prashant K SinghGenomics Shared Resource, Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Jianmin WangDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Anirban MaitraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pawel KalinskiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huamin WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wenting LiaoCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Scott I AbramsDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA.
Brahm H SegalDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Prasenjit DeyDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA. Electronic address: prasenjit.dey@roswellpark.org.
Roswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USSun Yat-sen University · CN
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7MProject 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2019 to 2023
$11.0MTargeting the Chemokine System to Sensitize Tumors to ImmunotherapyP01CA234212 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KALINSKI, PAWEL · 2020 to 2024
$10.1MNovel immunological biomarkers ovarian cancer prognosisR01CA188900 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., SEGAL, BRAHM H. · 2015 to 2019
$3.3MTranslational Applications in an Animal Model of Pancreatic Cystic Neoplasm and CancerR01CA218004 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2018 to 2021
$2.4MExploring Collateral Lethality for Development of Cancer TherapeuticsR01CA225955 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2018 to 2022
$2.3MRole of type 2 immune response in pancreatic cancer tumorigenesisR01CA262822 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DEY, PRASENJIT · 2021 to 2025
$2.2MMechanisms Underlying Functional Programs of Tumor-Associated MacrophagesR01CA172105 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I. · 2015 to 2019
$2.0MTargeting Malic Enzyme 3 as a Synthetic Lethality Target in Pancreatic CancerR00CA218891 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DEY, PRASENJIT · 2019 to 2021
$747kTargeting malic enzyme 3 as a synthetic lethality target in pancreatic cancerK99CA218891 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEY, PRASENJIT · 2018 to 2019
$171kNCI NIH HHS K99 CA218891NCI NIH HHS P01 CA117969NCI NIH HHS P01 CA234212NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221707NCI NIH HHS R00 CA218891NCI NIH HHS R01 CA172105NCI NIH HHS R01 CA188900NCI NIH HHS R01 CA218004NCI NIH HHS R01 CA225955NCI NIH HHS R01 CA262822
Abstract
T
Indexed as
Immunity, InnateMycobiomeAnimalsBiomarkersDisease Models, AnimalDisease ProgressionDisease SusceptibilityGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-33Lymphocyte CountLymphocytes, Tumor-InfiltratingMiceModels, BiologicalPancreatic NeoplasmsBiomarkersInterleukin-33anti-fungal therapyfungal mycobiomeIL-33ILC2innate lymphoid cellsintratumor-microbiomeKrasPDACTH2type 2 immune response
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.